THIS SITE IS FOR UK HEALTHCARE PROFESSIONALS ONLY

What are the
benefits of
VYEPTI IV?

VYEPTI® (EPTINEZUMAB) IS INDICATED FOR THE PROPHYLAXIS OF MIGRAINE IN ADULTS WHO HAVE AT LEAST 4 MIGRAINE DAYS PER MONTH1
PRESCRIBING INFORMATION AND ADVERSE EVENT REPORTING CAN BE ACCESSED VIA THE TABS AT THE TOP OF THIS PAGE

Designed for predictability, simplicity, and patient preference, VYEPTI supports patients with a reliable infusion-based approach

Scheduling

COMPLETE DOSE DELIVERED1

IV administration provides full systemic delivery of the prescribed dose, helping ensure predictable exposure compared with routes requiring absorption.1,2

Scheduling

Full Dose On Board From Day1

Because the dose is delivered directly into the circulation, treatment is fully administered during the infusion visit—no absorption step required.

Scheduling

Reduced Self-Administration Burden

Provider-administered IV treatment1 consolidates dosing into scheduled infusion visits, helping to decrease reliance on frequent self-injections.

Scheduling

Quarterly, Time-Efficient Visits

One 30-minute infusion every 12 weeks offers a predictable schedule1 that may align with patient preference for less frequent dosing.3

How does dosing burden compare between VYEPTI and oral or subcutaneous migraine preventives?


Average dosing interval of medication required for the prevention of migraine over a full 12-month treatment period

Just one 30-minute infusion every 12 weeks could help your patients escape the vicious cycle of worsening migraine1,4–6

This information is provided for illustrative purposes only. Refer to the individual product Summary of Product Characteristics for full prescribing information.

intravenous 100 mg infusions

(recommended dosing is 100 mg administered by intravenous infusion every 12 weeks1)

Oral preventive migraine medication

Rimegepant: One 75 mg tablet every other day7

x183

Atogepant: 10-60 mg tablets once daily; typical doses: 10 mg, 30 mg or 60 mg8

x365

Subcutaneous preventive migraine medication

Fremanezumab: subcutaneous 225 mg or 675 mg injections9

x12

Erenumab: subcutaneous 140 mg injections10

x13

Galcanezumab: subcutaneous 120 mg injections11

x12

In patients with prior inadequate response to other anti-CGRP mAbs*

The majority of infusion-related concerns were alleviated after starting VYEPTI12

Infusion concerns before and after starting VYEPTI12†

  • Extremely concerned
  • Very concerned
  • Moderately concerned
  • Slightly concerned
  • Not at all concerned

Adapted from Argoff C, et al. J Headache Pain. 2024

14%

After starting VYEPTI, the proportion of patients that reported being at least slightly concerned about infusions reduced from 62% (58/93) before starting VYEPTI to 14% (13/93)12†

94%

of patients (87/93) agreed or strongly agreed it was convenient to receive their treatment through an infusion12‡

* In this real-world study (N=94), 89% of patients had previously used a subcutaneous anti-CGRP mAb, 82% had used onabotulinumtoxinA, 74% had used an oral preventive, and 73% had used a gepant (including atogepant, ubrogepant, and rimegepant). Data shown are from an online patient survey. Self-reported survey data are subject to recall bias, and recall could have been further impacted in the 51% of patients who received ≥5 infusions.12
† Patients were instructed: “Please rate how much you agree or disagree with the following statement by placing a checkmark ✓ in the column which most closely fits your opinion.” I had concerns about receiving infusions; choices included: extremely concerned, very concerned, moderately concerned, slightly concerned, and not at all concerned.12
‡ Patients were instructed: “Please rate how much you agree or disagree with the following statement by placing a checkmark ✓ in the column which most closely fits your opinion.” I find it convenient to receive my treatment through an infusion; choices included: strongly agree, agree, undecided, disagree, and strongly disagree. All assessment data, including demographics, were summarised using descriptive techniques.12

Improved persistence with VYEPTI compared to subcutaneous anti-CGRPs reduces switch-related burden13,14

The probability of patients remaining on treatment was significantly higher with VYEPTI compared to subcutaneous anti-CGRP mAbs in the real world13*

Unadjusted probability of remaining on treatment13*†

Adapted from Charleston IV, et al. J Headache Pain. 2023.

The lower discontinuation rate with VYEPTI compared to SC anti-CGRPs may have been due to:13‡

A lower dosing frequency

Better treatment effectiveness or tolerability

Greater HCP involvement compared to self-administered SC anti-CGRPs

*Data based on 66,576 patients with migraine who had a most recent episode of migraine occurring between 25th June 2020-31st December 2021 and underwent a period of treatment with the same drug during which the patient fills the prescription no more than 15 days after exhausting the days’ supply of the current treatment.13

†Discontinuation was defined as a 15-day gap in therapy beginning from the date after the last day of therapy as indicated by the days’ supply of the drug.13

‡The collected data did not allow determination of why patients switched/discontinued medications.13

VYEPTI IV infusion could be the change that
your migraine patient needs

VYEPTI IS GENERALLY WELL TOLERATED IN PATIENTS WITH MIGRAINE1,16

The most common side effects are hypersensitivity reactions, infusion related reaction and fatigue. Most hypersensitivity reactions occurred during infusion and were not serious (reported in ~4% of VYEPTI patients and 2% of placebo patients in clinical studies). Infusion-related reactions occurred infrequently and in similar proportions of VYEPTI and placebo patients (<1%). Fatigue was most frequent on the day of the first infusion, and reported in ~3% of VYEPTI patients and 2% of placebo patients1

The treating healthcare professional should observe or monitor patients during and after the infusion in accordance with normal clinical practice1

WHAT NEEDS TO BE CONSIDERED WHEN ADMINISTERING VYEPTI IV?

For full details, please refer to the VYEPTI Summary of Product Characteristics before prescribing this medicine1

Patient

Which of your
patients could
benefit from
VYEPTI?

FIND OUT MORE
Patient

IV benefits
digital
leavepiece

DOWNLOAD

Resources

Vyepti IV Benefit Leavepiece

UK-VYEP-1018 | May 2026
DOWNLOAD

Argoff C, et al. 2024

UK-VYEP-1127 | May 2026
DOWNLOAD

Charleston IV, et al. 2023

UK-VYEP-1128 | May 2026
DOWNLOAD

CONTACT US

LET'S
CONNECT

Schedule a meeting about VYEPTI with your local Lundbeck representative

REQUEST NOW

HERE
TO HELP

Contact us with any general or
product-related queries

GET IN TOUCH

STAY
IN TOUCH

To receive information and
updates about VYEPTI,
sign up for promotional
communications from Lundbeck

SIGN UP